Reimbursement articles from across Nature Portfolio

A retrospective analysis shows that the IRA will not result in a large-scale defunding of biopharmaceutical innovation.

Co-developing a drug with a diagnostic to create a stratified medicine — a therapy that is targeted to a specific patient population on the basis of a clinical biomarker — presents challenges for product developers, regulators, payers and physicians. With the aim of developing a shared framework and tools for addressing these challenges, this article presents an analysis using data from case studies in oncology and Alzheimer's disease, coupled with integrated computational modelling of clinical outcomes and economic value, to quantify the effects of decisions on key issues such as the design of clinical trials.

Regulators and health technology assessment bodies discussed early experiences with pilot programmes in which they work together to provide drug developers with joint advice on the design of clinical trials.